GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Cyclically Adjusted Book per Share

Lumos Pharma (FRA:4NX1) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lumos Pharma's adjusted book value per share for the three months ended in Mar. 2024 was €1.920. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Lumos Pharma's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lumos Pharma was 10.10% per year. The lowest was 3.80% per year. And the median was 6.95% per year.

As of today (2024-05-21), Lumos Pharma's current stock price is €7.20. Lumos Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.00. Lumos Pharma's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lumos Pharma was 1.21. The lowest was 0.08. And the median was 0.29.


Lumos Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lumos Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Cyclically Adjusted Book per Share Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.45 21.13 - - -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lumos Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lumos Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Cyclically Adjusted PB Ratio falls into.



Lumos Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lumos Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.92/131.7762*131.7762
=1.920

Current CPI (Mar. 2024) = 131.7762.

Lumos Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 17.234 100.560 22.584
201409 17.601 100.428 23.095
201412 51.372 99.070 68.332
201503 67.897 99.621 89.812
201506 63.163 100.684 82.668
201509 57.802 100.392 75.872
201512 56.135 99.792 74.126
201603 49.513 100.470 64.941
201606 41.304 101.688 53.525
201609 38.116 101.861 49.310
201612 37.876 101.863 48.999
201703 32.933 102.862 42.190
201706 28.068 103.349 35.788
201709 25.668 104.136 32.481
201712 31.059 104.011 39.350
201803 27.093 105.290 33.909
201806 25.877 106.317 32.074
201809 25.324 106.507 31.332
201812 24.453 105.998 30.400
201903 22.867 107.251 28.096
201906 21.073 108.070 25.696
201909 18.921 108.329 23.016
201912 -12.904 108.420 -15.684
202003 13.264 108.902 16.050
202006 12.470 108.767 15.108
202009 12.135 109.815 14.562
202012 11.537 109.897 13.834
202103 10.986 111.754 12.954
202106 10.043 114.631 11.545
202109 9.573 115.734 10.900
202112 9.422 117.630 10.555
202203 8.889 121.301 9.657
202206 8.438 125.017 8.894
202209 8.182 125.227 8.610
202212 6.730 125.222 7.082
202303 5.869 127.348 6.073
202306 4.822 128.729 4.936
202309 3.979 129.860 4.038
202312 2.996 129.419 3.051
202403 1.920 131.776 1.920

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lumos Pharma  (FRA:4NX1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lumos Pharma was 1.21. The lowest was 0.08. And the median was 0.29.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lumos Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Industry
Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines